新靶标与化学干预研究中心线上学术报告会

时间：2022年6月30日上午10:00—11:00

线上参会方式：Zoom，会议ID：937 3687 4767

线下参会地点：图书馆8楼819会议室（根据疫情防控要求，线下参会人员仅限50人，请参会人员积极选择线上参会）

题目：Cancer Immunotherapy Beyond PD1/PD-L1 Inhibitors

 

 

报告人：Dr. Yuwen Zhu is currently an associate professor of Surgical Oncology Division at Department of Surgery, University of Colorado Anschutz Medical Campus. Dr. Zhu obtained his PhD in immunology at Mayo Clinic in 2006 and had been trained for over 12 years in cancer immunotherapy at Dr. Lieping Chen's laboratory across Mayo Clinic, Johns Hopkins Medical Institutions and Yale University. In 2013, Dr. Zhu joined as a faculty member at University of Colorado Anschutz Medical Campus (CU AMC). 

Dr. Zhu's research interest lies in the discovery of novel immunosuppressive pathways and their applications in cancer therapy. Dr. Zhu's early research work has contributed to the identification of several immunomodulatory interactions, including CD28/B7-H2, CD28H/B7-H5, and HVEM/SALM5. Dr. Zhu's research team at CU AMC has identified CD112R (also called as PVRIG) and GPR171 as two novel immune checkpoints important for cancer immunotherapy. His current work focuses on understanding how the tumor microenvironment inhibits T cell migration into tumors through vascular dysfunction and chemokine scavenging. Dr. Zhu has published over 30 peer-reviewed research journal articles, including Sci Transl Med, Nat Commun, J Exp Med and Cancer Res. His lab has been issued multiple patents which have been licensed to biotech companies for drug development.

 

 

校科研处，生命科学研究院

2022年6月27日